Experts believe the two drugs could be ‘the beginning of the end’ for the disease after initial trial results shown to slow dementia progression
In what is hoped could be a gamechanger in the battle to combat Alzheimer’s, scientists will unveil crucial findings tomorrow. Families affected by the disease hailed initial results of what is a second drug shown to slow dementia progression.
They are the first of a series of drugs going through trials that seem to interrupt the physical processes causing issues such as memory loss. Tomorrow manufacturer Eli Lilly will publish the full results for its drug donanemab which it previously claimed slowed mental decline by 36% by targeting a brain protein known as tau.
It comes a fortnight after the Mirror revealed TV presenter Fiona Phillips has been diagnosed with Alzheimer’s at the age of 62. She is now taking part in a clinical trial of a third drug. Writing for the Mirror, Dr Richard Oakley, associate director at the Alzheimer’s Society, said: “After 20 years with no new Alzheimer’s disease drugs in the UK, we now have two potential new drugs in 12 months..
This could be the beginning of the end for Alzheimer’s disease.”